Robert J. Mullin - Concepedia

Concepedia

Author

Robert J. Mullin

Research Triangle Park Foundation

Also Known As

R J Mullin, R. J. MULLIN, R. J. Mullin, R. Mullin, R.J. Mullin, Robert J Mullin, Robert J. Mullin, Robert Mullin

79

Publications

4.1K

Citations

21

H-Index

63

Concepts

All Affiliations

Research Triangle Park Foundation GlaxoSmithKline (United States)University of Minnesota Mayo Clinic Duke University

RJ

About

Robert J. Mullin is an author at Research Triangle Park Foundation specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	19	3.6K
2	Natural Sciences	8	8	272
3	Education	2	2	55
4	Health Sciences	2	2	761
5	Engineering	1	1	27

Robert J. Mullin

×

28

Publications

4.1K

Citations

21

H-Index

	Year	Citations
Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells Gottfried E. Konecny, Mark D. Pegram, Natarajan Venkatesan, Cancer Research Breast OncologyOncologyMedicineReceptor Tyrosine KinaseCell Lines	2006	904
The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. David W. Rusnak, Karen Lackey, Karen Affleck, PubMed PathologyCell ProliferationCell GrowthTumor BiologyOncology	2001	737
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways Wenle Xia, Robert J. Mullin, Barry R. Keith, Oncogene OncologyMedicineReceptor Tyrosine KinaseCancer BiologyDownstream Erk1/2	2002	664
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity Rakesh Kumar, Victoria B. Knick, Sharon K. Rudolph, Molecular Cancer Therapeutics ImmunologyPharmacotherapyBolus AdministrationTumor BiologyAngiogenesis	2007	512
The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. David W. Rusnak, Karen Affleck, Stuart Cockerill, PubMed Potential TherapyTumor BiologyOncologyDual Erbb-2/egfrReceptor Tyrosine Kinase	2001	297
Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb<sup>®</sup>, GW572016) in an expanded panel of human normal and tumour cell lines David W. Rusnak, Krystal J. Alligood, Robert J. Mullin, Cell Proliferation	2007	174
6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases Edgar R. Wood, Lisa M. Shewchuk, Byron Ellis, Proceedings of the National Academy of Sciences Combinatorial ChemistryMedicinal ChemistryBiochemistryCovalent BondMedicine	2008	110
Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors Tara Rheault, Thomas R. Caferro, Scott H. Dickerson, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryMedicinePharmacotherapyAnti-cancer AgentDrug Development	2008	83
Toward Antibody-directed Enzyme Prodrug Therapy with the T268G Mutant of Human Carboxypeptidase A1 and Novel in VivoStable Prodrugs of Methotrexate Gary K. Smith, Sheila D. Banks, Todd A. Blumenkopf, Journal of Biological Chemistry	1997	65
Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines Micheal D. Gaul, Yu Guo, Karen Affleck, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryMedicineRational Drug DesignPharmacotherapyBiological Evaluation	2003	57

Page 1